Akimitsu Hirai
Founder bei FUNPEP COMPANY LIMITED
Vermögen: 809 410 $ am 31.03.2024
Profil
Akimitsu Hirai is the founder of Lexwell Partners, established in 1999, where he holds the title of Representative Partner.
He is also the founder of FunPep Co., Ltd., established in 2013, where he holds the title of President & Representative Director.
Mr. Hirai's former jobs include being an Outside Director at RaQualia Pharma, Inc., a Director at Okinawa Protein Tomography Ltd., and an Auditor at REGiMMUNE Corp.
from 2013 to 2014.
Mr. Hirai received a graduate degree from the University of Washington in 1995 and a graduate degree from Keio University in 1983.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FUNPEP COMPANY LIMITED
2,69% | 31.12.2022 | 700 000 ( 2,69% ) | 809 410 $ | 31.03.2024 |
Aktive Positionen von Akimitsu Hirai
| Unternehmen | Position | Beginn |
|---|---|---|
| FUNPEP COMPANY LIMITED | Founder | 11.10.2013 |
| Lexwell Partners | Founder | 01.04.1999 |
Ehemalige bekannte Positionen von Akimitsu Hirai
| Unternehmen | Position | Ende |
|---|---|---|
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Director/Board Member | - |
Okinawa Protein Tomography Ltd.
 Okinawa Protein Tomography Ltd. Miscellaneous Commercial ServicesCommercial Services Okinawa Protein Tomography Ltd. provides polymeric molecular structure analysis services. Its technology allows imaging of macromolecules including proteins in multiple states at the single molecule-level by combining conventional electron tomography and a specifically designed 3D reconstruction program known as COMET. The firm analyzes data of molecular structures of protein samples. The company was founded by Akira Kamei on June 25, 2014 and is headquartered in Uruma, Japan. | Director/Board Member | - |
| RAQUALIA PHARMA INC. | Director/Board Member | - |
Ausbildung von Akimitsu Hirai
| University of Washington | Graduate Degree |
| Keio University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| RAQUALIA PHARMA INC. | Health Technology |
| FUNPEP COMPANY LIMITED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
| Lexwell Partners | |
Okinawa Protein Tomography Ltd.
Okinawa Protein Tomography Ltd. Miscellaneous Commercial ServicesCommercial Services Okinawa Protein Tomography Ltd. provides polymeric molecular structure analysis services. Its technology allows imaging of macromolecules including proteins in multiple states at the single molecule-level by combining conventional electron tomography and a specifically designed 3D reconstruction program known as COMET. The firm analyzes data of molecular structures of protein samples. The company was founded by Akira Kamei on June 25, 2014 and is headquartered in Uruma, Japan. | Commercial Services |
